Notice Number: NOT-AI-05-043

Key Dates
Release Date: May 19, 2005
Receipt Date(s): September 26, 2005
Peer Review Date(s): January, 2006
Earliest Anticipated Start Date: May 3, 2006
Expiration Date: September 27, 2005

The Division of Acquired Immune Deficiency Syndrome (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is committed to the development of efficacious vaccines against HIV and AIDS for worldwide use in stemming the AIDS epidemic. To augment the vaccine product pipeline, DAIDS is seeking opportunities to advance vaccine concepts toward the product stage via a focused, development-based approach. Specifically, the goal of this Broad Agency Announcement (BAA) is to solicit proposals for the development of new, safe, and immunogenic vaccine candidates that merit further evaluation in large human trials.

This HIV Vaccine Design and Development Teams (herein referred to as HIV Vaccine Teams) BAA seeks to fund consortia of scientists with product development experience from industry and/or academia who have (1) identified a promising vaccine candidate, and (2) devised a comprehensive strategic research plan for targeted development of the vaccine candidate into a product suitable for testing in humans. It is a requirement of the contract that an HIV Vaccine Team advances the vaccine concept(s) along a well-defined development path in a timely manner to a vaccine product and into clinical testing by the beginning of the fifth year of the award period. Offerors are strongly encouraged, but not required, to conduct phase I/II trials in collaboration with an NIAID/DAIDS-supported clinical trials network, such as the HIV/AIDS Vaccine Trials Network (the HVTN; http://www.hvtn.org/) for preventive vaccines, the AIDS Clinical Trials Groups (ACTG; http://aactg.s-3.com/) for therapeutic vaccines, or the restructured HIV/AIDS Clinical Trials Networks currently being solicited under NIAID RFA-AI-05-001(http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-05-001.html), Leadership for HIV/AIDS Clinical Trials Networks.

It is anticipated that up to four (4) cost reimbursement, completion type contracts will be awarded for a period of five (5) years, beginning approximately May 3, 2006. NIH-NIAID-DAIDS-BAA-06-19 will be available electronically on or about May 26, 2005, and may be accessed through the NIAID Contract Management Program (CMP) Home Page by using the following electronic address and instructions: Access the CMP Home Page by using http://www.niaid.nih.gov/contract and select the RFPs link, then select RFP-NIH-NIAID-DAIDS-BAA-06-19.  It will also be posted on FedBizOpps at http://www.fedbizopps.gov/.

This advertisement does not commit the Government to award a contract. Any reasonable offeror may submit a proposal that will be considered by the Government. No collect calls will be accepted. No facsimile transmissions will be accepted. See Government-wide Numbered Note 26.

Inquiries

For questions or further information, contact:

Jill Johnson
Contracting Specialist
National Institute of Allergy and Infectious Diseases
Room 2230, MSC-7610
6700-B Rockledge Drive
Bethesda, MD 20892-7620
Telephone: 301-451-6396
FAX: 301-402-0972
Email: [email protected]

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

			Department of Health and Human Services (HHS)
NIH... Turning Discovery Into Health®